Co-Diagnostics Earnings Call: Pipeline Progress, Cash Strain

Co-Diagnostics ((CODX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Co-Diagnostics’ latest earnings call painted a mixed picture, blending evident strategic momentum with mounting financial strain. Management highlighted milestones in relisting, regional expansion and pipeline progress, yet these advances sit against collapsing revenue, a sizable noncash impairment and shrinking cash reserves that together underscore substantial execution and funding risk.

NASDAQ Relisting Restores Market Standing

Co-Diagnostics successfully appealed its prior listing issue and saw its shares relisted on NASDAQ, removing a major overhang for investors. Management framed the relisting as a reset moment, allowing leadership to shift focus from compliance battles to operational execution and commercialization priorities.

CoSara India: License Win and Regional Reach

Through its CoSara venture, the company secured a CDSCO license to manufacture the PCR Pro instrument in India, enabling local production of instruments and consumables. At the same time, distribution rights were expanded to Bangladesh, Pakistan, Nepal and Sri Lanka, lifting the South Asia addressable market from roughly $11 billion to about $13 billion.

TB Strategy Tied to WHO Guidance

Management spotlighted tuberculosis as a flagship opportunity, with clinical performance studies planned in India, the world’s largest TB market. Updated WHO guidance favors near point-of-care molecular testing and tongue swab sampling, and Co-Dx’s SARS platform-based TB assays are designed to align with these standards.

Promising TB Data and Commercial Timeline

Preclinical third-party studies indicated that the company’s TB test performance was comparable to or better than existing molecular alternatives. With this data foundation, Co-Diagnostics is targeting commercial launch of its TB test in India by the third quarter of 2026 through the CoSara joint venture structure.

CoMira JV Builds MENA Manufacturing Beachhead

In the Middle East, the CoMira joint venture with Arabian Eagle is progressing toward local manufacturing capabilities in Saudi Arabia. Lease arrangements and operational preparations are advancing, positioning CoMira to become the Kingdom’s first domestic molecular diagnostics producer and to serve 18 additional MENA markets.

Clinical Pipeline Advances With 1,200+ Enrollments

The upper respiratory multiplex program is moving forward across roughly eight U.S. clinical sites, where more than 1,200 patients have already been enrolled. To accelerate time-to-market, Co-Diagnostics plans an initial FDA submission focused on flu A, flu B and RSV, preserving flexibility to add a COVID target later.

COVID Target Deferred from Initial Multiplex Filing

Despite its pandemic heritage, the company chose to exclude the COVID target from the first U.S. multiplex submission due to a shortage of COVID-positive samples at trial locations. Management stressed that COVID could be reintroduced in a subsequent filing, though that will likely require additional clinical work and regulatory discussions.

IP Portfolio Strengthens Global Position

Co-Diagnostics reported new international patent grants covering key components of the Co-Dx PCR platform, including protection in Australia and Japan. These patents are intended to shield the company’s technology as it moves toward broader commercialization and supports its strategy of international expansion.

AI Platform Extends Beyond Primer Design

The company is broadening its Co-Dx primer AI capabilities to cover assay design, interpretation of diagnostic results and predictive analytics. Management described multiple AI models already deployed, viewing the platform as a longer-term lever for both revenue potential and operational efficiency.

Cost Discipline Drives Adjusted EBITDA Improvement

Excluding the large noncash impairment, operating expenses moved meaningfully lower across the board, with R&D down 9.1 percent, sales and marketing down 46.7 percent and G&A down 43.8 percent. On this adjusted basis, EBITDA loss improved to $28.0 million from a $33.5 million loss, a roughly 16.4 percent year-over-year gain.

Revenue Collapse Highlights Commercial Gap

Revenue fell sharply to just $0.6 million from $3.9 million a year earlier, an 84.6 percent decline heavily tied to lower grant income. Product revenue was only $0.4 million, down 50 percent, reflecting the company’s still-limited commercial footprint as it prioritizes development and regulatory work over broad product launches.

Noncash Impairment Masks Underlying OpEx Trend

A noncash impairment charge of about $18.9 million tied to in-process R&D drove reported operating expenses up to $50.6 million from $43.0 million. Management emphasized that, when this impairment is excluded, underlying operating costs actually declined, supporting its narrative of tightening expense control.

Net Loss Widens Despite Per-Share Optics

The company’s net loss increased to $46.9 million from $37.6 million, a roughly 24.7 percent deterioration in bottom-line performance. GAAP loss per share improved modestly to $35.25 from $37.22, but this was driven by changes in share count rather than any improvement in fundamental profitability.

Cash Burn and Liquidity Remain Major Concerns

Year-end cash, cash equivalents and marketable securities dropped to $11.9 million from $29.7 million, a decline of around 60 percent that heightens liquidity concerns. Net cash used in operations remained sizable at $29.0 million, underscoring ongoing cash burn and the importance of securing new funding sources.

Pre-Commercial Platform Limits Near-Term Sales

Many elements of the Co-Dx PCR platform remain pre-commercial in key target markets because required regulatory approvals are still pending. As a result, product revenue stayed minimal in the period, with management signaling that commercial scale will only emerge after current development and approval milestones are met.

Financing and Strategic Options Still Unsettled

Leadership indicated it is exploring multiple financing avenues, including potential equity or debt raises as well as strategic partnerships. The team is also evaluating a possible SPAC transaction for CoSara, but stressed there is no certainty on if, when or on what terms any deal or capital raise might materialize.

Guidance: Losses to Continue as Pipeline Builds

Management guided investors to expect continued operating losses as it pushes toward commercialization while managing a constrained balance sheet. Priorities include FDA submission for the flu A, flu B and RSV multiplex, TB launch in India by late 2026, progressing CoMira to manufacturing readiness, expanding the IP estate and pursuing a mix of non-dilutive grants and capital market options to extend runway.

Co-Diagnostics’ earnings call outlined a company rich in strategic initiatives but short on immediate revenue and liquidity comfort. For investors, the story hinges on whether the firm can convert its relisting, regional partnerships, TB opportunity and AI-enhanced platform into meaningful sales before cash pressures force unfavorable financing or strategic compromises.